FMR LLC - 15 Jan 2026 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role
Other*, 10%+ Owner
Signature
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Issuer symbol
GPCR
Transactions as of
15 Jan 2026
Net transactions value
-$1,453,753
Form type
4
Filing time
20 Jan 2026, 09:22:14 UTC
Previous filing
10 Dec 2025
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FMR LLC Other*, 10%+ Owner 245 SUMMER STREET, BOSTON /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 20 Jan 2026 0000315066

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GPCR Ordinary Shares 20,502 15 Jan 2026 F-Prime Capital Partners Life Sciences Advisors Fund VI LP
holding GPCR Ordinary Shares 241,275 15 Jan 2026 F-Prime Capital Partners Life Sciences Fund VI LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GPCR American Depositary Shares Sale $38,176 -465 -8.5% $82.10 5,005 15 Jan 2026 Ordinary Shares 1,395 F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1, F2
transaction GPCR American Depositary Shares Sale $27,506 -330 -6.6% $83.35 4,675 15 Jan 2026 Ordinary Shares 990 F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1, F3
transaction GPCR American Depositary Shares Sale $46,489 -552 -12% $84.22 4,123 15 Jan 2026 Ordinary Shares 1,656 F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1, F4
transaction GPCR American Depositary Shares Sale $1,701 -20 -0.49% $85.04 4,103 15 Jan 2026 Ordinary Shares 60 F-Prime Capital Partners Life Sciences Advisors Fund VI LP F1, F5
transaction GPCR American Depositary Shares Sale $449,662 -5,477 -8.5% $82.10 58,864 15 Jan 2026 Ordinary Shares 16,431 F-Prime Capital Partners Life Sciences Fund VI LP LP F1, F2
transaction GPCR American Depositary Shares Sale $323,398 -3,880 -6.6% $83.35 54,984 15 Jan 2026 Ordinary Shares 11,640 F-Prime Capital Partners Life Sciences Fund VI LP F1, F3
transaction GPCR American Depositary Shares Sale $547,262 -6,498 -12% $84.22 48,486 15 Jan 2026 Ordinary Shares 19,494 F-Prime Capital Partners Life Sciences Fund VI LP F1, F4
transaction GPCR American Depositary Shares Sale $19,559 -230 -0.47% $85.04 48,256 15 Jan 2026 Ordinary Shares 690 F-Prime Capital Partners Life Sciences Fund VI LP F1, F5
holding GPCR American Depositary Shares 1,515,558 15 Jan 2026 Ordinary Shares 4,546,674 Shares held by persons and entities whose shares are subject to reporting by the undersigned F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.
F2 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information
F3 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information
F4 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information
F5 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.